{
  "abstract": "Disease-targeted therapies (DTTs) for Alzheimer's disease (AD) represent a major advance, yet challenges remain on how best to interpret and communicate their benefits. As clinical development increasingly targets the earliest stages of AD (before symptoms emerge and early symptomatic AD), there is a need for novel, complementary endpoints and improved communication of treatment benefits. The Global CEO Initiative on Alzheimer's Disease convened a multi-stakeholder working group to develop recommendations for improving the design and communication of endpoints in AD clinical trials. In the near term, communication can be improved by contextualizing treatment effects at the individual level, including framing benefits in terms of responder analyses and \"time saved\" over defined timeframes. In parallel, continued development of complementary endpoints is needed to enable more sensitive, scalable, and patient-centered measurements aligned with early intervention. These recommendations aim to support stakeholders in evaluating and communicating the meaningful benefits of current and emerging therapies.",
  "abstract_shown": true,
  "affiliations": [
    "Banner Alzheimer's Institute and University of Arizona College of Medicine, Phoenix, Arizona, USA.",
    "Pentara Corporation, Salt Lake City, Utah, USA.",
    "Global Alzheimer's Platform Foundation, Washington, District of Columbia, USA.",
    "Bristol Myers Squibb, Princeton, New Jersey, USA.",
    "Perelman School of Medicine, University of Pennsylvania, Philadelphia, New Jersey, USA.",
    "ki:elements GmbH, Saarbrücken, Germany.",
    "Department of Clinical Pharmacy, University of Colorado Anschutz, Aurora, Colorado, USA.",
    "UsAgainstAlzheimer's, Washington, District of Columbia, USA.",
    "The Global CEO Initiative on Alzheimer's Disease, Wayne, Pennsylvania, USA.",
    "Department of Psychiatry and Psychotherapy, LMU Hospital, Ludwig-Maximilians-University, Munich, Germany.",
    "Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.",
    "Voices of Alzheimer's, Washington, District of Columbia, USA."
  ],
  "article_type": "other",
  "arxiv": null,
  "author_total": 16,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Pierre N Tariot"
    },
    {
      "affs": [
        1
      ],
      "name": "Samuel P Dickson"
    },
    {
      "affs": [
        2
      ],
      "name": "John Dwyer"
    },
    {
      "affs": [
        3
      ],
      "name": "Carlos Granda"
    },
    {
      "affs": [
        2
      ],
      "name": "Lynne Hughes"
    },
    {
      "affs": [
        4
      ],
      "name": "Jason Karlawish"
    },
    {
      "affs": [
        5
      ],
      "name": "Nicklas Linz"
    },
    {
      "affs": [
        6
      ],
      "name": "Kavita V Nair"
    },
    {
      "affs": [
        7
      ],
      "name": "Russ Paulsen"
    },
    {
      "affs": [
        8
      ],
      "name": "Daniel Pawson"
    },
    {
      "affs": [
        9
      ],
      "name": "Robert Perneczky"
    },
    {
      "affs": [
        10
      ],
      "name": "Suzanne E Schindler"
    },
    {
      "affs": [
        8
      ],
      "name": "Emily Scholler"
    },
    {
      "affs": [
        11
      ],
      "name": "James Taylor"
    },
    {
      "affs": [
        8
      ],
      "name": "Benjamin Tiede"
    },
    {
      "affs": [
        7,
        8
      ],
      "name": "George Vradenburg"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/3rn2nkp9fwcrj.bib",
  "cited_by": 0,
  "doi": "10.1002/alz.71951",
  "fulltext_url": "https://europepmc.org/articles/PMC13722601",
  "id": "3rn2nkp9fwcrj",
  "issns": [
    "1552-5260",
    "1552-5279"
  ],
  "landing_url": "https://europepmc.org/article/MED/42963333",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Perspective"
    ],
    [
      "openalex",
      "2737|Alzheimer's disease research and treatments"
    ]
  ],
  "openalex": "W7224996084",
  "pdf_url": "https://europepmc.org/articles/PMC13722601?pdf=render",
  "pmcid": "PMC13722601",
  "pmid": "42963333",
  "published": "2026-10-01",
  "publisher": "Wiley",
  "ris": "https://research.draconitic.com/paper/3rn2nkp9fwcrj.ris",
  "sources": [
    {
      "first_seen": "2026-11-02T03:21:43Z",
      "native_id": "MED:42963333",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42963333"
    },
    {
      "first_seen": "2026-11-04T12:21:23Z",
      "native_id": "PMC13722601",
      "source": "pmc",
      "url": "https://doi.org/10.1002/alz.71951"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2737|Alzheimer's disease research and treatments",
      "subfield": "physiology"
    }
  ],
  "title": "Expert perspectives on the design and communication of endpoints in Alzheimer's disease clinical trials.",
  "title_text": "Expert perspectives on the design and communication of endpoints in Alzheimer's disease clinical trials.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-04T12:21:23Z",
  "url": "https://research.draconitic.com/paper/3rn2nkp9fwcrj",
  "venue": "Alzheimer's & dementia : the journal of the Alzheimer's Association",
  "versions": []
}